To safely reach the highest recommended semaglutide dose, it's important to increase the dosage slowly, following health guidelines and professional advice
Review Type: 351(k) BLA, Standard Review Submission Date: January 28, 2024 Elamipretide (New Molecular Entity) Developer: Stealth BioTherapeutics Modality: Peptide PDUFA Date: January 29, 2025 Indication/Description: Cardiovascular congenital diseases / Mitochondrial protective peptide bound to cardiolipin, for treating Barth syndrome Review Type: Priority Review (Initially Standard Review, changed to Priority Review at the request of Stealth Bio) Submission Date: January 2024 Review Status: Initial submission in August 2021, FDA issued a Refuse to File (RTF) letter in October 2021
"We will no longer tolerate profiteering and price gouging from 'big pharma.' But again it was really the countries that forced 'big pharma' to do things that, frankly, I'm not sure they felt comfortable doing," he continued
How does this compare to Nutrex's capsule Carnitine product